title: Short-term effects of 2% atorvastatin dentifrice as an adjunct to periodontal therapy: a randomized double-masked clinical trial.
abstract: BACKGROUND
  The pleiotropic effects of statins, such as immunomodulation and anti-inflammatory effects, may also improve periodontal conditions. The aim of the present study is to assess the effectiveness of a dentifrice medicated with 2% atorvastatin in improving clinical periodontal parameters as a complement to non-surgical periodontal treatment (NSPT).
  
  
  METHODS
  A randomized, double-masked clinical trial was performed with two parallel groups: 1) atorvastatin group (NSPT plus medicated 2% atorvastatin dentifrice) and 2) placebo group (NSPT plus placebo dentifrice). The effectiveness of these treatments was assessed using periodontal measurements obtained at baseline and 1 month later. The measurements were probing depth (PD), clinical attachment level (CAL), bleeding on probing (BOP), gingival index (GI), and periodontal inflamed surface area (PISA). Multiple linear regression models were used to compare outcome variables after adjusting for sex, diabetes, and tobacco use.
  
  
  RESULTS
  A total of 36 individuals participated in this study (atorvastatin group, n = 18; placebo group, n = 18). Both groups showed improvements in periodontal parameters. The atorvastatin group showed a decrease of 297.63 mm(2) in PISA (95% confidence interval = 76.04 to 519.23; P = 0.01), which was significantly greater than the reduction observed in the placebo group. There was also a significantly greater reduction in mean PD, percentage of sites with PD ≥5 mm, mean CAL, percentage of sites with CAL ≥5 mm, BOP, and GI in the atorvastatin group compared with the placebo group.
  
  
  CONCLUSIONS
  NSPT plus 2% atorvastatin medicated dentifrice was more effective in improving clinical periodontal parameters than NSPT plus a placebo dentifrice.
authors: Department of Oral and Maxillofacial Surgery, Faculty of Dentistry, University of Los Andes, Santiago, Chile.
authors: David R
authors: DR
authors: Rosenberg
authors: Catherine X
authors: CX
authors: Andrade
authors: Alejandra P
authors: AP
authors: Chaparro
authors: Carolina M
authors: CM
authors: Inostroza
authors: Valeria
authors: V
authors: Ramirez
authors: Déborah
authors: D
authors: Violant
authors: José
authors: J
authors: Nart
mesh_terms: D000328:Adult; D000893:Anti-Inflammatory Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D000069059:Atorvastatin / Q000008:administration & dosage / Q000627:therapeutic use*; D003131:Combined Modality Therapy; D003802:Dentifrices / Q000627:therapeutic use*; D048909:Diabetes Complications; D004311:Double-Blind Method; D005260:Female; D005500:Follow-Up Studies; D005884:Gingival Hemorrhage / Q000188:drug therapy / Q000628:therapy; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000008:administration & dosage / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D009911:Oral Hygiene Index; D017622:Periodontal Attachment Loss / Q000188:drug therapy / Q000628:therapy; D057747:Periodontal Debridement / Q000379:methods; D010512:Periodontal Index; D010514:Periodontal Pocket / Q000188:drug therapy / Q000628:therapy; D010518:Periodontitis / Q000188:drug therapy* / Q000628:therapy; D010919:Placebos; D012737:Sex Factors; D064424:Tobacco Use; D016896:Treatment Outcome
chemical_list: D000893:Anti-Inflammatory Agents; D003802:Dentifrices; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D010919:Placebos; D000069059:Atorvastatin
keywords: Chronic periodontitis; clinical trial; dentifrices.